Polly A Newcomb1, Michael N Passarelli2, Amanda I Phipps2, Garnet L Anderson2, Jean Wactawski-Wende2, Gloria Y F Ho2, Mary Jo O'Sullivan2, Rowan T Chlebowski2. 1. Polly A. Newcomb, Michael N. Passarelli, Amanda I. Phipps, and Garnet L. Anderson, Fred Hutchinson Cancer Research Center; Polly A. Newcomb, Michael N. Passarelli, Amanda I. Phipps, and Garnet L. Anderson, School of Public Health, University of Washington, Seattle, WA; Jean Wactawski-Wende, School of Public Health and Health Professions, University at Buffalo, The State University of New York, Buffalo; Gloria Y.F. Ho, Albert Einstein College of Medicine, Bronx, NY; Mary Jo O'Sullivan, University of Miami, Miami, FL; and Rowan T. Chlebowski, Los Angeles Biomedical Research Institute at Harbor-University of California Los Angeles Medical Center, Torrance, CA. pnewcomb@fhcrc.org. 2. Polly A. Newcomb, Michael N. Passarelli, Amanda I. Phipps, and Garnet L. Anderson, Fred Hutchinson Cancer Research Center; Polly A. Newcomb, Michael N. Passarelli, Amanda I. Phipps, and Garnet L. Anderson, School of Public Health, University of Washington, Seattle, WA; Jean Wactawski-Wende, School of Public Health and Health Professions, University at Buffalo, The State University of New York, Buffalo; Gloria Y.F. Ho, Albert Einstein College of Medicine, Bronx, NY; Mary Jo O'Sullivan, University of Miami, Miami, FL; and Rowan T. Chlebowski, Los Angeles Biomedical Research Institute at Harbor-University of California Los Angeles Medical Center, Torrance, CA.
Abstract
PURPOSE: Bisphosphonates are common medications used for the treatment of osteoporosis and are also used to reduce metastases to bone in patients with cancer. Several studies, including the Women's Health Initiative (WHI), have found that use of bisphosphonates is associated with reduced risk of developing breast cancer, but less is known about associations with other common malignancies. This study was aimed at examining the effects of bisphosphonates on the risk of endometrial cancer. METHODS: We evaluated the relationship between use of oral bisphosphonates and endometrial cancer risk in a cohort of 89,918 postmenopausal women participating in the WHI. A detailed health interview was conducted at baseline, and bisphosphonate use was ascertained from an inventory of regularly used medications at baseline and over follow-up. All women had an intact uterus at the time of study entry. RESULTS: During a median follow-up of 12.5 years, 1,123 women were diagnosed with incident invasive endometrial cancer. Ever use of bisphosphonates was associated with reduced endometrial cancer risk (adjusted hazard ratio, 0.80; 95% CI, 0.64 to 1.00; P = .05), with no interactions observed with age, body mass index, or indication for use. CONCLUSION: In this large prospective cohort of postmenopausal women, bisphosphonate use was associated with a statistically significant reduction in endometrial cancer risk.
PURPOSE:Bisphosphonates are common medications used for the treatment of osteoporosis and are also used to reduce metastases to bone in patients with cancer. Several studies, including the Women's Health Initiative (WHI), have found that use of bisphosphonates is associated with reduced risk of developing breast cancer, but less is known about associations with other common malignancies. This study was aimed at examining the effects of bisphosphonates on the risk of endometrial cancer. METHODS: We evaluated the relationship between use of oral bisphosphonates and endometrial cancer risk in a cohort of 89,918 postmenopausal women participating in the WHI. A detailed health interview was conducted at baseline, and bisphosphonate use was ascertained from an inventory of regularly used medications at baseline and over follow-up. All women had an intact uterus at the time of study entry. RESULTS: During a median follow-up of 12.5 years, 1,123 women were diagnosed with incident invasive endometrial cancer. Ever use of bisphosphonates was associated with reduced endometrial cancer risk (adjusted hazard ratio, 0.80; 95% CI, 0.64 to 1.00; P = .05), with no interactions observed with age, body mass index, or indication for use. CONCLUSION: In this large prospective cohort of postmenopausal women, bisphosphonate use was associated with a statistically significant reduction in endometrial cancer risk.
Authors: Jennifer Hays; Julie R Hunt; F Allan Hubbell; Garnet L Anderson; Marian Limacher; Catherine Allen; Jacques E Rossouw Journal: Ann Epidemiol Date: 2003-10 Impact factor: 3.797
Authors: J David Curb; Anne McTiernan; Susan R Heckbert; Charles Kooperberg; Janet Stanford; Michael Nevitt; Karen C Johnson; Lori Proulx-Burns; Lisa Pastore; Michael Criqui; Sandra Daugherty Journal: Ann Epidemiol Date: 2003-10 Impact factor: 3.797
Authors: L A Brinton; M L Berman; R Mortel; L B Twiggs; R J Barrett; G D Wilbanks; L Lannom; R N Hoover Journal: Am J Obstet Gynecol Date: 1992-11 Impact factor: 8.661
Authors: Frederic Amant; Philippe Moerman; Patrick Neven; Dirk Timmerman; Erik Van Limbergen; Ignace Vergote Journal: Lancet Date: 2005 Aug 6-12 Impact factor: 79.321
Authors: P A Newcomb; A Trentham-Dietz; K M Egan; L Titus-Ernstoff; J A Baron; B E Storer; W C Willett; M J Stampfer Journal: Am J Epidemiol Date: 2001-06-01 Impact factor: 4.897
Authors: Marcia L Stefanick; Barbara B Cochrane; Judith Hsia; David H Barad; James H Liu; Susan R Johnson Journal: Ann Epidemiol Date: 2003-10 Impact factor: 3.797
Authors: Venkateshwar Madka; Gaurav Kumar; Gopal Pathuri; Yuting Zhang; Stanley Lightfoot; Adam S Asch; Altaf Mohammed; Vernon E Steele; Chinthalapally V Rao Journal: Cancer Prev Res (Phila) Date: 2019-11-07